3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Unknown
1
Terminated
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
38
Precursor Cell Lymphoblastic Leukemia-Lymphoma
14
Myelodysplastic Syndromes
10
Burkitt Lymphoma
9
Lymphoma, Mantle-Cell
6
Leukemia, Biphenotypic, Acute
6
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Myeloproliferative Disorders
4
Lymphoma, Non-Hodgkin
4
Lymphoma
4
Leukemia
4
Recurrence
3
Lymphoma, Large B-Cell, Diffuse
3
Leukemia, Myelomonocytic, Chronic
3
Down Syndrome
3
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
2
Lymphoma, Follicular
2
Leukemia, Myeloid, Accelerated Phase
2
Leukemia, Monocytic, Acute
2
Blast Crisis
2
Vasculitis, Central Nervous System
1
Stiff-Person Syndrome
1
Sarcoma, Myeloid
1
Rasmussen subacute encephalitis
1
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
1
Plasmablastic Lymphoma
1
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
1
Pathologic Complete Response
1
Opsoclonus-Myoclonus Syndrome
1
Neuromyelitis Optica
1
Interventions
pembrolizumab
2
venetoclax
1
taxane
1
sargramostim
1
rucaparib
1
olaparib
1
lentiviral minigene vaccine of COVID-19 coronavirus
1
Platinum
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Observation
1
Nivolumab
1
Monatide (IMS 3015)
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Epirubicin
1
Decitabine
1
Cytarabine
1
Cyclophosphamide
1
Carboplatin
1
Capecitabine
1
Azacitidine
1
Antimetabolites
1
Anthracyclines
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Pathologic Complete Response
×
Cytarabine
×
Clear all
NCT04229979
2025-10-01
REGAL
Sellas Life Sciences Group
Phase 3
Active not recruiting
127 enrolled